Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11373073rdf:typepubmed:Citationlld:pubmed
pubmed-article:11373073lifeskim:mentionsumls-concept:C0040300lld:lifeskim
pubmed-article:11373073lifeskim:mentionsumls-concept:C0019247lld:lifeskim
pubmed-article:11373073lifeskim:mentionsumls-concept:C0311400lld:lifeskim
pubmed-article:11373073lifeskim:mentionsumls-concept:C2924406lld:lifeskim
pubmed-article:11373073lifeskim:mentionsumls-concept:C0028580lld:lifeskim
pubmed-article:11373073lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:11373073lifeskim:mentionsumls-concept:C2003903lld:lifeskim
pubmed-article:11373073lifeskim:mentionsumls-concept:C1518918lld:lifeskim
pubmed-article:11373073pubmed:issue1lld:pubmed
pubmed-article:11373073pubmed:dateCreated2001-5-24lld:pubmed
pubmed-article:11373073pubmed:abstractTextA principal problem in understanding the functional genomics of a pathology is the wide-reaching biochemical effects that occur when the expression of a given protein is altered. To complement the information available to bioinformatics through genomic and proteomic approaches, a novel method of providing metabolite profiles for a disease is suggested, using pattern recognition coupled with (1)H NMR spectroscopy. Using this technique the mdx mouse, a model of Duchenne muscular dystrophy (DMD) was examined. Dystrophic tissue had distinct metabolic profiles not only for cardiac and other muscle tissues, but also in the cerebral cortex and cerebellum, where the role of dystrophin is still controversial. These metabolic ratios were expressed crudely as biomarker ratios to demonstrate the effectiveness of the approach at separating dystrophic from control tissue (cardiac (taurine/creatine): mdx = 2.08 +/- 0.04, control 1.55 +/- 0.04, P < 0.005; cortex (phosphocholine/taurine): mdx = 1.28 +/- 0.12, control = 0.83 +/- 0.05, P < 0.01; cerebellum (glutamate/creatine): mdx = 0.49 +/- 0.03, control = 0.34 +/- 0.03, P < 0.01). This technique produced new metabolic biomarkers for following disease progression but also demonstrated that many metabolic pathways are perturbed in dystrophic tissue.lld:pubmed
pubmed-article:11373073pubmed:languageenglld:pubmed
pubmed-article:11373073pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11373073pubmed:citationSubsetIMlld:pubmed
pubmed-article:11373073pubmed:statusMEDLINElld:pubmed
pubmed-article:11373073pubmed:monthJunlld:pubmed
pubmed-article:11373073pubmed:issn0003-2697lld:pubmed
pubmed-article:11373073pubmed:authorpubmed-author:SanoMMlld:pubmed
pubmed-article:11373073pubmed:authorpubmed-author:WilliamsH JHJlld:pubmed
pubmed-article:11373073pubmed:authorpubmed-author:GriffinJ LJLlld:pubmed
pubmed-article:11373073pubmed:authorpubmed-author:ClarkeKKlld:pubmed
pubmed-article:11373073pubmed:authorpubmed-author:NicholsonJ...lld:pubmed
pubmed-article:11373073pubmed:authorpubmed-author:SCHMMlld:pubmed
pubmed-article:11373073pubmed:copyrightInfoCopyright 2001 Academic Press.lld:pubmed
pubmed-article:11373073pubmed:issnTypePrintlld:pubmed
pubmed-article:11373073pubmed:day1lld:pubmed
pubmed-article:11373073pubmed:volume293lld:pubmed
pubmed-article:11373073pubmed:ownerNLMlld:pubmed
pubmed-article:11373073pubmed:authorsCompleteYlld:pubmed
pubmed-article:11373073pubmed:pagination16-21lld:pubmed
pubmed-article:11373073pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:meshHeadingpubmed-meshheading:11373073...lld:pubmed
pubmed-article:11373073pubmed:year2001lld:pubmed
pubmed-article:11373073pubmed:articleTitleMetabolic profiling of genetic disorders: a multitissue (1)H nuclear magnetic resonance spectroscopic and pattern recognition study into dystrophic tissue.lld:pubmed
pubmed-article:11373073pubmed:affiliationBiological Chemistry, Biomedical Sciences, Imperial College, Sir Alexander Fleming Building, London, SW7 2AZ, United Kingdom. j.griffin@ic.ac.uklld:pubmed
pubmed-article:11373073pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11373073pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11373073pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:13405entrezgene:pubmedpubmed-article:11373073lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11373073lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11373073lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11373073lld:pubmed